Ampio Pharmaceuticals, Inc.
5445 DTC Parkway, P4
202 articles with Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory status of Ampion™.
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it had received an initial response from the U.S. Food and Drug Administration (FDA), Office of Tissue and Advanced Therapies division regarding the Company's submission of a proposed trial design for the treatment of KL4 Osteoarthritis patients with Ampion
Ampio Pharmaceuticals, Inc. today updates the regulatory status of Ampion.
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion™ for the treatment of severe osteoarthritis-of-the-knee (OAK).
Ampio Pharmaceuticals, Inc. today provided an update of the ongoing Company activities required to file a Biologics License Application (BLA) for Ampion™ for the treatment of severe Osteoarthritis of the knee (OAK).
Retains Board of Director and Scientific Advisory Board positions
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ampio Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ampio Pharmaceuticals, Inc. of the October 24, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
The offering is expected to close on or about August 13, 2018, subject to customary closing conditions.
AMPIO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Ampio Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE-MKT:AMPE).
The U.S. Food and Drug Administration (FDA) rejected Englewood, Colorado-based Ampio Pharmaceuticals’ Biologics License Application (BLA) for its drug for osteoarthritis of the knee, Ampion.
Ampio Pharmaceuticals, Inc., a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering.
Ampio Pharmaceuticals, Inc. announced a basic science manuscript entitled "The Anti-Inflammatory Effect of LMWF5A and N-Acetyl Kynurenine on Macrophages: Involvement of Aryl Hydrocarbon Receptor in Mechanism of Action" authored by Dr. Bar-Or and prominent clinicians has been published online in Biochemistry and Biophysics Reports.
Ampio Pharmaceuticals, Inc. announced two peer-reviewed articles on the clinical application of Ampion™ are now available online.
Ampio Pharmaceuticals, Inc. announced regulatory and IP activities
Ampio Pharmaceuticals, Inc. to address significant inflammatory conditions for which limited treatment options exist, today announced updates to shareholders that address questions recently posed to management by shareholders.
The Pivotal Trial Results on Ampion™ (AP-003-C) Was Accepted for Publication in a Peer-Reviewed Medical Journal
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the publication entitled: "Intra-articular injection of the anti-inflammatory compound LMWF-5A (Ampion™) in adults with severe osteoarthritis: a double-blind prospective randomized controlled multicenter safety and efficacy trial"
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announces the Company has retained PAREXEL® (www.parexel.com/) to assist in preparing and presenting the Biologics License Application (BLA) for Ampion™ for the treatment of osteoarthritis-of-the-knee (OAK) to the FDA.
Ampio Pharmaceuticals, Inc. announced their 2017 financial results during a conference call hosted on Wednesday, March 7th at 5:00 pm EST. Included below are highlighted disclosures from the corporate update and filed Annual report on Form 10K.
Ampio today reported a heavy schedule of meetings throughout the four-day conference, predominately with significant pharma companies discussing the successful clinical results of the company's second pivotal phase III trial announced Dec. 14, 2017.
If approved, Ampion would be the first intra-articular injection to treat the signs and symptoms of patients with severe osteoarthritis of the knee.